<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">ssmu</journal-id><journal-title-group><journal-title xml:lang="ru">Бюллетень сибирской медицины</journal-title><trans-title-group xml:lang="en"><trans-title>Bulletin of Siberian Medicine</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1682-0363</issn><issn pub-type="epub">1819-3684</issn><publisher><publisher-name>Siberian State Medical University, the Ministry of Healthcare of the Russian Federation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.20538/1682-0363-2024-4-55-63</article-id><article-id custom-type="elpub" pub-id-type="custom">ssmu-5869</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL PAPERS</subject></subj-group></article-categories><title-group><article-title>Фенотипический профиль моноцитов крови и опухольассоциированных макрофагов во взаимосвязи с экспрессией галектинов 1 и 3 при раке толстой кишки</article-title><trans-title-group xml:lang="en"><trans-title>Phenotypic profile of blood monocytes and tumor-associated macrophages in relation to the expression of galectins 1 and 3 in colorectal cancer</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3210-0298</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Курносенко</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kurnosenko</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Курносенко Анна Васильевна – аспирант, кафедра патофизиологии, 634055, г. Томск, Московский тракт, 2;</p><p>врач-онколог, 634040, г. Томск, пр. Ленина, 115</p></bio><bio xml:lang="en"><p>2, Moscow Trakt, Tomsk, 634050;</p><p>115, Lenina Av., Tomsk, 634050</p></bio><email xlink:type="simple">kurnosenko.av@ssmu.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3148-0900</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Рейнгардт</surname><given-names>Г. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Reingardt</surname><given-names>G. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Рейнгардт Глеб Вадимович – ассистент, кафедра патофизиологии, 634055, г. Томск, Московский тракт, 2;</p><p>врач-онколог, 634040, г. Томск, пр. Ленина, 115</p></bio><bio xml:lang="en"><p>2, Moscow Trakt, Tomsk, 634050;</p><p>115, Lenina Av., Tomsk, 634050</p></bio><email xlink:type="simple">glebreyngardt@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2005-305X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Полетика</surname><given-names>В. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Poletika</surname><given-names>V. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Полетика Вадим Сергеевич – канд. мед. наук, доцент кафедры патофизиологии, </p><p>634055, г. Томск, Московский тракт, 2</p></bio><bio xml:lang="en"><p>2, Moscow Trakt, Tomsk, 634050</p></bio><email xlink:type="simple">vpoletika@yandex.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7156-2471</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Колобовникова</surname><given-names>Ю. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kolobovnikova</surname><given-names>Yu. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Колобовникова Юлия Владимировна – д-р мед. наук, доцент, зав. кафедрой нормальной физиологии, профессор кафедры патофизиологии, </p><p>634055, г. Томск, Московский тракт, 2</p></bio><bio xml:lang="en"><p>2, Moscow Trakt, Tomsk, 634050</p></bio><email xlink:type="simple">kolobovnikova.julia@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3468-6154</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Чумакова</surname><given-names>С. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Chumakova</surname><given-names>S. P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Чумакова Светлана Петровна – д-р мед. наук, доцент, профессор кафедры патофизиологии,</p><p>634055, г. Томск, Московский тракт, 2</p></bio><bio xml:lang="en"><p>2, Moscow Trakt, Tomsk, 634050</p></bio><email xlink:type="simple">chumakova_s@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9457-8879</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Уразова</surname><given-names>О. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Urazova</surname><given-names>O. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Уразова Ольга Ивановна – д-р мед. наук, профессор, чл.-корр. РАН, зав. кафедрой патофизиологии, </p><p>634055, г. Томск, Московский тракт, 2</p></bio><bio xml:lang="en"><p>2, Moscow Trakt, Tomsk, 634050</p></bio><email xlink:type="simple">urazova.oi@ssmu.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0961-7336</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Грищенко</surname><given-names>М. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Grishchenko</surname><given-names>M. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Грищенко Максим Юрьевич – канд. мед. наук, доцент, зав. кафедрой хирургии с курсом мобилизационной подготовки и медицины катастроф, 634055, г. Томск, Московский тракт, 2;</p><p>гл. врач, 634040, г. Томск, пр. Ленина, 115</p></bio><bio xml:lang="en"><p>2, Moscow Trakt, Tomsk, 634050;</p><p>115, Lenina Av., Tomsk, 634050</p></bio><email xlink:type="simple">grischenko.mj@ssmu.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8509-9921</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Чурина</surname><given-names>Е. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Churina</surname><given-names>E. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Чурина Елена Георгиевна – д-р мед. наук, профессор кафедры патофизиологии, </p><p>634055, г. Томск, Московский тракт, 2</p></bio><bio xml:lang="en"><p>2, Moscow Trakt, Tomsk, 634050</p></bio><email xlink:type="simple">lena1236@yandex.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0007-7947-360X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гамирова</surname><given-names>К. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Gamirova</surname><given-names>K. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Гамирова Кристина Анатольевна – аспирант, кафедра организации здравоохранения и общественного здоровья, 634055, г. Томск, Московский тракт, 2;</p><p>врач-онколог, 634040, г. Томск, пр. Ленина, 115</p></bio><bio xml:lang="en"><p>2, Moscow Trakt, Tomsk, 634050;</p><p>115, Lenina Av., Tomsk, 634050</p></bio><email xlink:type="simple">k.a.gamirova@tomonco.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Сибирский государственный медицинский университет (СибГМУ);&#13;
Томский областной онкологический диспансер (ТООД)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Siberian State Medical University;&#13;
Tomsk Regional Cancer Center</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Сибирский государственный медицинский университет (СибГМУ)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Siberian State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>20</day><month>01</month><year>2025</year></pub-date><volume>23</volume><issue>4</issue><fpage>55</fpage><lpage>63</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Курносенко А.В., Рейнгардт Г.В., Полетика В.С., Колобовникова Ю.В., Чумакова С.П., Уразова О.И., Грищенко М.Ю., Чурина Е.Г., Гамирова К.А., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Курносенко А.В., Рейнгардт Г.В., Полетика В.С., Колобовникова Ю.В., Чумакова С.П., Уразова О.И., Грищенко М.Ю., Чурина Е.Г., Гамирова К.А.</copyright-holder><copyright-holder xml:lang="en">Kurnosenko A.V., Reingardt G.V., Poletika V.S., Kolobovnikova Y.V., Chumakova S.P., Urazova O.I., Grishchenko M.Y., Churina E.G., Gamirova K.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://bulletin.ssmu.ru/jour/article/view/5869">https://bulletin.ssmu.ru/jour/article/view/5869</self-uri><abstract><sec><title>Цель</title><p>Цель. Выявить особенности субпопуляционного состава моноцитов крови и макрофагов опухоли во взаимосвязи с плазменной концентрацией и внутриопухолевой экспрессией галектинов 1 и 3 у больных раком толстой кишки.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Обследованы 23 больных колоректальным раком (МКБ С18–20) – 5 мужчин и 18 женщин, средний возраст (63,8 ± 9,4) лет. Группу контроля составили здоровые добровольцы, группу сравнения – пациенты с аденомами толстой кишки, сопоставимые по полу и возрасту. Материалом исследования являлись цельная кровь и биоптаты опухоли. Концентрацию галектинов 1 и 3 в крови определяли методом иммуноферментного анализа, содержание опухолевых галектин-1+ и галектин-3+ клеток – методом иммуногистохимии. Подсчет субпопуляций моноцитов крови выполняли методом проточной цитофлуориметрии, определение иммунофенотипов М1 (CD68+CD80+) и М2d (CD68+CD206+) макрофагов в опухолевой ткани – методом иммунофлуоресценции. Результаты исследования обрабатывали статистическими методами с применением программного пакета Jamovi 2.3.21 для Windows.</p></sec><sec><title>Результаты</title><p>Результаты. У больных раком толстой кишки (РТК) установлена положительная связь между высокой плазменной концентрацией галектинов 1 и 3 и нарушением баланса моноцитов крови в виде снижения относительного содержания классических CD14++CD16– моноцитов и, напротив, увеличения численности неклассических CD14+ CD16++ и переходных CD14+ CD16– клеток. Относительное количество М1 (CD68+CD80+) и М2d (CD68+CD206+) макрофагов в образцах тканей РТК оказалось сопоставимым и не зависело от уровня галектинов 1 и 3 в крови и опухоли. У пациентов с аденомами толстой кишки преобладала М2d-субпопуляция опухоль-ассоциированных макрофагов (p = 0,031).</p></sec><sec><title>Заключение</title><p>Заключение. У больных РТК галектины 1 и 3 оказывают модулирующее влияние на соотношение неклассических CD14+CD16++, переходных CD14+CD16– и классических CD14++CD16– моноцитов в крови и не влияют на формирование М1/М2d-экспрессионного профиля опухоль-ассоциированных макрофагов.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim. To identify the features of the subpopulation composition of blood monocytes and tumor macrophages in relation to the plasma concentration and intratumoral expression of galectins 1 and 3 in patients with colorectal cancer.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. A total of 23 patients with colorectal cancer (ICD C18-20) were examined – 5 men and 18 women (average age 63.8 ± 9.4 years). The control group consisted of healthy volunteers; the comparison group encompassed age- and sex-matched patients with colon adenomas. The study materials included whole blood and tumor biopsies. The concentration of galectins 1 and 3 in the blood was determined by enzyme-linked immunosorbent assay, the content of tumor galectin-1+ and galectin-3+ cells – by immunohistochemistry. Subpopulations of blood monocytes were evaluated by flow cytometry; the macrophage immunophenotypes M1 (CD68+ CD80+ ) and M2d (CD68+ CD206+ ) in tumor tissues were determined using immunofluorescence staining. Statistical processing of the research results was performed by the Jamovi 2.3.21 software package for Windows.</p></sec><sec><title>Results</title><p>Results. In patients with colorectal cancer (CRC), a positive relationship was identified between high plasma concentrations of galectins 1 and 3 and an imbalance of blood monocytes manifested by a decrease in the relative count of classical CD14++CD16- monocytes and, conversely, an increase in the number of non-classical CD14+CD16++ and intermediate CD14+ CD16- cells. The relative numbers of M1 (CD68+CD80+) and M2d (CD68+CD206+) macrophages in CRC tissue samples turned out to be comparable and did not depend on the level of galectins 1 and 3 in the blood and tumor. In patients with colon adenomas, the M2d subpopulation of tumorassociated macrophages was predominant (p = 0.031).</p></sec><sec><title>Conclusion</title><p>Conclusion. In patients with CRC, galectins 1 and 3 have a modulating effect on the ratio of non-classical CD14+CD16++, intermediate CD14+CD16- , and classical CD14++CD16- monocytes in the blood and do not affect the M1/M2d expression profile of tumor-associated macrophages.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>галектины</kwd><kwd>моноциты</kwd><kwd>макрофаги</kwd><kwd>рак толстой кишки</kwd><kwd>иммунофенотип</kwd></kwd-group><kwd-group xml:lang="en"><kwd>galectins</kwd><kwd>monocytes</kwd><kwd>macrophages</kwd><kwd>colorectal cancer</kwd><kwd>immunophenotype</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2021;71(3):209–249. DOI: 10.3322/caac.21660.</mixed-citation><mixed-citation xml:lang="en">Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2021;71(3):209–249. DOI: 10.3322/caac.21660.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Siegel R.L., Wagle N.S., Cercek A., Smith R.A., Jemal A. Colorectal cancer statistics, 2023. CA Cancer J. Clin. 2023;73(3):233–254. DOI: 10.3322/caac.21772.</mixed-citation><mixed-citation xml:lang="en">Siegel R.L., Wagle N.S., Cercek A., Smith R.A., Jemal A. Colorectal cancer statistics, 2023. CA Cancer J. Clin. 2023;73(3):233–254. DOI: 10.3322/caac.21772.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Каприн А.Д., Старинский В.В., Шахзадова А.О. Состояние онкологической помощи населению России в 2021 году. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России. 2022:239.</mixed-citation><mixed-citation xml:lang="en">Каприн А.Д., Старинский В.В., Шахзадова А.О. Состояние онкологической помощи населению России в 2021 году. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России. 2022:239.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Чердынцева Н.В., Митрофанова И.В., Булдаков М.А., Стахеева М.Н., Патышева М.Р., Завьялова М.В. и др. Макрофаги и опухолевая прогрессия: на пути к макрофагспецифичной терапии. Бюллетень сибирской медицины. 2017;16(4):61–74.</mixed-citation><mixed-citation xml:lang="en">Чердынцева Н.В., Митрофанова И.В., Булдаков М.А., Стахеева М.Н., Патышева М.Р., Завьялова М.В. и др. Макрофаги и опухолевая прогрессия: на пути к макрофагспецифичной терапии. Бюллетень сибирской медицины. 2017;16(4):61–74.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Chou F.C., Chen H.Y., Kuo C.C., Sytwu H.K. Role of galectins in tumors and in clinical immunotherapy. Int. J. Mol. Sci. 2018;19(2):430. DOI: 10.3390/ijms19020430.</mixed-citation><mixed-citation xml:lang="en">Chou F.C., Chen H.Y., Kuo C.C., Sytwu H.K. Role of galectins in tumors and in clinical immunotherapy. Int. J. Mol. Sci. 2018;19(2):430. DOI: 10.3390/ijms19020430.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Orozco C.A., Martinez-Bosch N., Guerrero P.E., Vinaixa J., Dalotto-Moreno T., Iglesias M. et al. Targeting galectin-1 inhibits pancreatic cancer progression by modulating tumor-stroma crosstalk. Proc. Natl. Acad. Sciю USA. 2018;115(16):e3769– 778. DOI: 10.1073/pnas.1722434115.</mixed-citation><mixed-citation xml:lang="en">Orozco C.A., Martinez-Bosch N., Guerrero P.E., Vinaixa J., Dalotto-Moreno T., Iglesias M. et al. Targeting galectin-1 inhibits pancreatic cancer progression by modulating tumor-stroma crosstalk. Proc. Natl. Acad. Sciю USA. 2018;115(16):e3769– 778. DOI: 10.1073/pnas.1722434115.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Lin Y.H., Qiu D.C., Chang W.H., Yeh Y.Q., Jeng U.S., Liu F.T. et al. The intrinsically disordered N-terminal domain of galectin-3 dynamically mediates multisite self-association of the protein through fuzzy interactions. J. Biol. Chem. 2017;292(43):17845–17856. DOI: 10.1074/jbc.M117.802793.</mixed-citation><mixed-citation xml:lang="en">Lin Y.H., Qiu D.C., Chang W.H., Yeh Y.Q., Jeng U.S., Liu F.T. et al. The intrinsically disordered N-terminal domain of galectin-3 dynamically mediates multisite self-association of the protein through fuzzy interactions. J. Biol. Chem. 2017;292(43):17845–17856. DOI: 10.1074/jbc.M117.802793.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Патышева М.Р., Стахеева М.Н., Ларионова И.В., Тарабановская Н.А., Григорьева Е.С., Слонимская Е.М. и др. Моноциты при злокачественных новообразованиях: перспективы и точки приложения для диагностики и терапии. Бюллетень сибирской медицины. 2019;18(1):60–75. DOI: 10.20538/1682-0363-2019-1-60-75.</mixed-citation><mixed-citation xml:lang="en">Патышева М.Р., Стахеева М.Н., Ларионова И.В., Тарабановская Н.А., Григорьева Е.С., Слонимская Е.М. и др. Моноциты при злокачественных новообразованиях: перспективы и точки приложения для диагностики и терапии. Бюллетень сибирской медицины. 2019;18(1):60–75. DOI: 10.20538/1682-0363-2019-1-60-75.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Zwager M.C., Bense R., Waaijer S., Qiu S.Q., Timmer-Bosscha H., de Vries E.G.E. et al. Assessing the role of tumour-associated macrophage subsets in breast cancer subtypes using digital image analysis. Breast Cancer Res. Treat. 2023;198(1):11–22. DOI: 10.1007/s10549-022-06859-y.</mixed-citation><mixed-citation xml:lang="en">Zwager M.C., Bense R., Waaijer S., Qiu S.Q., Timmer-Bosscha H., de Vries E.G.E. et al. Assessing the role of tumour-associated macrophage subsets in breast cancer subtypes using digital image analysis. Breast Cancer Res. Treat. 2023;198(1):11–22. DOI: 10.1007/s10549-022-06859-y.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Колобовникова Ю.В., Уразова О.И., Полетика В.С., Рейнгардт Г.В., Романова Е.В., Курносенко А.В., и др. Особенности экспрессии галектинов 1 и 3 при раке толстого кишечника во взаимосвязи с клинико-морфологическими параметрами опухоли. Фундаментальная и клиническая медицина. 2021;6(4):45–53.</mixed-citation><mixed-citation xml:lang="en">Колобовникова Ю.В., Уразова О.И., Полетика В.С., Рейнгардт Г.В., Романова Е.В., Курносенко А.В., и др. Особенности экспрессии галектинов 1 и 3 при раке толстого кишечника во взаимосвязи с клинико-морфологическими параметрами опухоли. Фундаментальная и клиническая медицина. 2021;6(4):45–53.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Ge X.N., Ha S.G., Liu F.T., Rao S.P., Sriramarao P. Eosinophil-expressed galectin-3 regulates cell trafficking and migration. Front. Pharmacol. 2013;4:37. DOI: 10.3389/fphar.2013.00037.</mixed-citation><mixed-citation xml:lang="en">Ge X.N., Ha S.G., Liu F.T., Rao S.P., Sriramarao P. Eosinophil-expressed galectin-3 regulates cell trafficking and migration. Front. Pharmacol. 2013;4:37. DOI: 10.3389/fphar.2013.00037.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Cornejo-García J.A., Romano A., Guéant-Rodríguez R.M., Oussalah A., Blanca-López N., Gaeta F. et al. A non-synonymous polymorphism in galectin-3 lectin domain is associated with allergic reactions to beta-lactam antibiotics. Pharmacogenomics J. 2016;16(1):79–82. DOI: 10.1038/tpj.2015.24.</mixed-citation><mixed-citation xml:lang="en">Cornejo-García J.A., Romano A., Guéant-Rodríguez R.M., Oussalah A., Blanca-López N., Gaeta F. et al. A non-synonymous polymorphism in galectin-3 lectin domain is associated with allergic reactions to beta-lactam antibiotics. Pharmacogenomics J. 2016;16(1):79–82. DOI: 10.1038/tpj.2015.24.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Chetry M., Thapa S., Hu X., Song Y., Zhang J., Zhu H. et al. The role of galectins in tumor progression, treatment and prognosis of gynecological cancers. J. Cancer. 2018;9(24):4742– 4755. DOI: 10.7150/jca.23628.</mixed-citation><mixed-citation xml:lang="en">Chetry M., Thapa S., Hu X., Song Y., Zhang J., Zhu H. et al. The role of galectins in tumor progression, treatment and prognosis of gynecological cancers. J. Cancer. 2018;9(24):4742– 4755. DOI: 10.7150/jca.23628.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Ito K., Stannard K., Gabutero E., Clark A.M., Neo S.Y., Onturk S. et al. Galectin-1 as a potent target for cancer therapy: role in the tumor microenvironment. Cancer Metastasis Rev. 2012;31(3–4):763–778. DOI: 10.1007/s10555-012-9388-2.</mixed-citation><mixed-citation xml:lang="en">Ito K., Stannard K., Gabutero E., Clark A.M., Neo S.Y., Onturk S. et al. Galectin-1 as a potent target for cancer therapy: role in the tumor microenvironment. Cancer Metastasis Rev. 2012;31(3–4):763–778. DOI: 10.1007/s10555-012-9388-2.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Iqbal A.J., Sampaio A.L.F., Maione F., Greco K.V., Niki T., Hirashima M. et al. Endogenous galectin-1 and acute inflammation: emerging notion of a galectin-9 pro-resolving effect. Am. J. Pathol. 2011;178(3):1201–1209. DOI: 10.1016/j.ajpath.2010.11.073.</mixed-citation><mixed-citation xml:lang="en">Iqbal A.J., Sampaio A.L.F., Maione F., Greco K.V., Niki T., Hirashima M. et al. Endogenous galectin-1 and acute inflammation: emerging notion of a galectin-9 pro-resolving effect. Am. J. Pathol. 2011;178(3):1201–1209. DOI: 10.1016/j.ajpath.2010.11.073.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Rabinovich G.A., Conejo-García J.R.. Shaping the immune landscape in cancer by galectin-driven regulatory pathways. J. Mol. Biol. 2016;428(16):3266–3281. DOI: 10.1016/j.jmb.2016.03.021.</mixed-citation><mixed-citation xml:lang="en">Rabinovich G.A., Conejo-García J.R.. Shaping the immune landscape in cancer by galectin-driven regulatory pathways. J. Mol. Biol. 2016;428(16):3266–3281. DOI: 10.1016/j.jmb.2016.03.021.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Якушина В.Д., Васильева О.А., Рязанцева Н.В., Новицкий В.В., Савельева О.Е., Прохоренко Т.С. и др. Галектин-1: роль в формировании особенностей врожденного и приобретенного иммунитета. Медицинская иммунология. 2012;14(1-2):21–32. DOI: 10.15789/1563-0625-2012-1-2- 21-32.</mixed-citation><mixed-citation xml:lang="en">Якушина В.Д., Васильева О.А., Рязанцева Н.В., Новицкий В.В., Савельева О.Е., Прохоренко Т.С. и др. Галектин-1: роль в формировании особенностей врожденного и приобретенного иммунитета. Медицинская иммунология. 2012;14(1-2):21–32. DOI: 10.15789/1563-0625-2012-1-2- 21-32.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Kianoush F., Nematollahi M., Waterfield J.D., Brunette D.M. Regulation of RAW264.7 macrophage polarization on smooth and rough surface topographies by galectin-3. J. Biomed. Mater. Res. A. 2017;105(9):2499–2509. DOI: 10.1002/jbm.a.36107.</mixed-citation><mixed-citation xml:lang="en">Kianoush F., Nematollahi M., Waterfield J.D., Brunette D.M. Regulation of RAW264.7 macrophage polarization on smooth and rough surface topographies by galectin-3. J. Biomed. Mater. Res. A. 2017;105(9):2499–2509. DOI: 10.1002/jbm.a.36107.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Novak R., Dabelic S., Dumic J. Galectin-1 and galectin-3 expression profiles in classically and alternatively activated human macrophages. Biochim. Biophys. Acta. 2012;1820(9):1383– 1390. DOI: 10.1016/j.bbagen.2011.11.014.</mixed-citation><mixed-citation xml:lang="en">Novak R., Dabelic S., Dumic J. Galectin-1 and galectin-3 expression profiles in classically and alternatively activated human macrophages. Biochim. Biophys. Acta. 2012;1820(9):1383– 1390. DOI: 10.1016/j.bbagen.2011.11.014.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Dragomir A.C.D., Sun R., Choi H., Laskin J.D., Laskin D.L. Role of galectin-3 in classical and alternative macrophage activation in the liver following acetaminophen intoxication. J. Immunol. 2012;189(12):5934–5941. DOI: 10.4049/jimmunol.1201851.</mixed-citation><mixed-citation xml:lang="en">Dragomir A.C.D., Sun R., Choi H., Laskin J.D., Laskin D.L. Role of galectin-3 in classical and alternative macrophage activation in the liver following acetaminophen intoxication. J. Immunol. 2012;189(12):5934–5941. DOI: 10.4049/jimmunol.1201851.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Сарбаева Н.Н., Пономарева Ю.В., Милякова М.Н. Ма крофаги: разнообразие фенотипов и функций, взаимодействие с чужеродными материалами. Гены и клетки. 2016;11(1):9–17. DOI: 10.23868/gc120550.</mixed-citation><mixed-citation xml:lang="en">Сарбаева Н.Н., Пономарева Ю.В., Милякова М.Н. Ма крофаги: разнообразие фенотипов и функций, взаимодействие с чужеродными материалами. Гены и клетки. 2016;11(1):9–17. DOI: 10.23868/gc120550.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Капитанова К.С., Науменко В.А., Гаранина А.С., Мельников П.А., Абакумов М.А., Алиева И.Б. Перспективы использования наночастиц для репрограммирования опухолевых макрофагов в иммунотерапии злокачественных новообразований. Биохимия. 2019;84(7):934–952. DOI: 10.1134/S0320972519070054.</mixed-citation><mixed-citation xml:lang="en">Капитанова К.С., Науменко В.А., Гаранина А.С., Мельников П.А., Абакумов М.А., Алиева И.Б. Перспективы использования наночастиц для репрограммирования опухолевых макрофагов в иммунотерапии злокачественных новообразований. Биохимия. 2019;84(7):934–952. DOI: 10.1134/S0320972519070054.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Жгулева А.С., Зементова М.С., Сельков С.А., Соколов Д.И. Макрофаги М1/М2: происхождение, фенотип, способы получения, взаимодействие с естественными киллерами и трофобластом. Медицинская иммунология. 2024;26(3):425–448. DOI: 10.15789/1563-0625-MMO-2877.</mixed-citation><mixed-citation xml:lang="en">Жгулева А.С., Зементова М.С., Сельков С.А., Соколов Д.И. Макрофаги М1/М2: происхождение, фенотип, способы получения, взаимодействие с естественными киллерами и трофобластом. Медицинская иммунология. 2024;26(3):425–448. DOI: 10.15789/1563-0625-MMO-2877.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Correa S.G., Sotomayor C.E., Aoki M.P., Maldonado C.A., Rabinovich G.A. Opposite effects of galectin-1 on alternative metabolic pathways of L-arginine in resident, inflammatory, and activated macrophages. Glycobiology. 2003;13(2):119– 128. DOI: 10.1093/glycob/cwg010.</mixed-citation><mixed-citation xml:lang="en">Correa S.G., Sotomayor C.E., Aoki M.P., Maldonado C.A., Rabinovich G.A. Opposite effects of galectin-1 on alternative metabolic pathways of L-arginine in resident, inflammatory, and activated macrophages. Glycobiology. 2003;13(2):119– 128. DOI: 10.1093/glycob/cwg010.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Грачев А.Н., Самойлова Д.В., Рашидова М.А., Петренко А.А., Ковалева О.В. Макрофаги, ассоциированные с опухолью: современное состояние исследований и перспективы клинического использования. Успехи молекулярной онкологии. 2018;5(4):20–28.</mixed-citation><mixed-citation xml:lang="en">Грачев А.Н., Самойлова Д.В., Рашидова М.А., Петренко А.А., Ковалева О.В. Макрофаги, ассоциированные с опухолью: современное состояние исследований и перспективы клинического использования. Успехи молекулярной онкологии. 2018;5(4):20–28.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Barrionuevo P., Beigier-Bompadre M., Ilarregui J.M., Toscano M.A., Bianco G.A., Isturiz M.A. et al. A novel function for galectin-1 at the crossroad of innate and adaptive immunity: galectin-1 regulates monocyte/macrophage physiology through a nonapoptotic ERK-dependent pathway. J. Immunol. 2007;178(1):436–445. DOI: 10.4049/jimmunol.178.1.436.</mixed-citation><mixed-citation xml:lang="en">Barrionuevo P., Beigier-Bompadre M., Ilarregui J.M., Toscano M.A., Bianco G.A., Isturiz M.A. et al. A novel function for galectin-1 at the crossroad of innate and adaptive immunity: galectin-1 regulates monocyte/macrophage physiology through a nonapoptotic ERK-dependent pathway. J. Immunol. 2007;178(1):436–445. DOI: 10.4049/jimmunol.178.1.436.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Baran B., Bechyne I., Siedlar M., Szpak K., Mytar B., Sroka J. et al. Blood monocytes stimulate migration of human pancreatic carcinoma cells in vitro: the role of tumour necrosis factor- alpha. Eur. J. Cell Biol. 2009;88(12):743–752. DOI: 10.1016/j.ejcb.2009.08.002.</mixed-citation><mixed-citation xml:lang="en">Baran B., Bechyne I., Siedlar M., Szpak K., Mytar B., Sroka J. et al. Blood monocytes stimulate migration of human pancreatic carcinoma cells in vitro: the role of tumour necrosis factor- alpha. Eur. J. Cell Biol. 2009;88(12):743–752. DOI: 10.1016/j.ejcb.2009.08.002.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Wu K., Lin K., Li X., Yuan X., Xu P., Ni P. et al. Redefining tumor-associated macrophage subpopulations and functions in the tumor microenvironment. Front. Immunol. 2020;11:1731. DOI: 10.3389/fimmu.2020.01731.</mixed-citation><mixed-citation xml:lang="en">Wu K., Lin K., Li X., Yuan X., Xu P., Ni P. et al. Redefining tumor-associated macrophage subpopulations and functions in the tumor microenvironment. Front. Immunol. 2020;11:1731. DOI: 10.3389/fimmu.2020.01731.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Sindrilaru A., Peters T., Wieschalka S., Baican C., Baican A., Peter H. et al. An unrestrained proinflammatory M1 macrophage population induced by iron impairs wound healing in humans and mice. J. Clin. Invest. 2011;121(3):985–997. DOI: 10.1172/JCI44490.</mixed-citation><mixed-citation xml:lang="en">Sindrilaru A., Peters T., Wieschalka S., Baican C., Baican A., Peter H. et al. An unrestrained proinflammatory M1 macrophage population induced by iron impairs wound healing in humans and mice. J. Clin. Invest. 2011;121(3):985–997. DOI: 10.1172/JCI44490.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Gong D., Shi W., Yi S., Chen H., Groffen J., Heisterkamp N. TGFβ signaling plays a critical role in promoting alternative macrophage activation. BMC Immunol. 2012;13:31. DOI: 10.1186/1471-2172-13-31.</mixed-citation><mixed-citation xml:lang="en">Gong D., Shi W., Yi S., Chen H., Groffen J., Heisterkamp N. TGFβ signaling plays a critical role in promoting alternative macrophage activation. BMC Immunol. 2012;13:31. DOI: 10.1186/1471-2172-13-31.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Bill R., Wirapati P., Messemaker M., Roh W., Zitti B., Duval F. et al. CXCL9:SPP1 macrophage polarity identifies a network of cellular programs that control human cancers. Science. 2023;381(6657):515–524. DOI: 10.1126/science.ade2292.</mixed-citation><mixed-citation xml:lang="en">Bill R., Wirapati P., Messemaker M., Roh W., Zitti B., Duval F. et al. CXCL9:SPP1 macrophage polarity identifies a network of cellular programs that control human cancers. Science. 2023;381(6657):515–524. DOI: 10.1126/science.ade2292.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Jayasingam S.D., Citartan M., Thang T.H., Mat Zin A.A., Ang K.C., Ch’ng E.S. Evaluating the polarization of tumor-associated macrophages into M1 and M2 phenotypes in human cancer tissue: technicalities and challenges in routine clinical practice. Front. Oncol. 2020;24(9):1512. DOI: 10.3389/fonc.2019.01512.</mixed-citation><mixed-citation xml:lang="en">Jayasingam S.D., Citartan M., Thang T.H., Mat Zin A.A., Ang K.C., Ch’ng E.S. Evaluating the polarization of tumor-associated macrophages into M1 and M2 phenotypes in human cancer tissue: technicalities and challenges in routine clinical practice. Front. Oncol. 2020;24(9):1512. DOI: 10.3389/fonc.2019.01512.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Dunstan R.W., Wharton K.A., Quigley C., Lowe A. The use of immunohistochemistry for biomarker assessment – can it compete with other technologies? Toxicol. Pathol. 2011;39(6):988–1002. DOI: 10.1177/0192623311419163.</mixed-citation><mixed-citation xml:lang="en">Dunstan R.W., Wharton K.A., Quigley C., Lowe A. The use of immunohistochemistry for biomarker assessment – can it compete with other technologies? Toxicol. Pathol. 2011;39(6):988–1002. DOI: 10.1177/0192623311419163.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Da C., Mc K., Va M., An O., Yv B. CD68/macrosialin: not just a histochemical marker. Lab. Invest. 2017;97(1):4–13. DOI: 10.1038/labinvest.2016.116.</mixed-citation><mixed-citation xml:lang="en">Da C., Mc K., Va M., An O., Yv B. CD68/macrosialin: not just a histochemical marker. Lab. Invest. 2017;97(1):4–13. DOI: 10.1038/labinvest.2016.116.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Fan W., Yang X., Huang F., Tong X., Zhu L. The Second Clinical Medical College ZCMU. Identification of CD206 as a potential biomarker of cancer stemlike cells and therapeutic agent in liver cancer. Oncology Letters. 2019;18(3):3218– 3226. DOI: 10.3892/ol.2019.10673.</mixed-citation><mixed-citation xml:lang="en">Fan W., Yang X., Huang F., Tong X., Zhu L. The Second Clinical Medical College ZCMU. Identification of CD206 as a potential biomarker of cancer stemlike cells and therapeutic agent in liver cancer. Oncology Letters. 2019;18(3):3218– 3226. DOI: 10.3892/ol.2019.10673.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
